Literature DB >> 22994804

Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients.

T Akimova1, B M Kamath, J W Goebel, K E C Meyers, E B Rand, A Hawkins, M H Levine, J C Bucuvalas, W W Hancock.   

Abstract

In a cross-sectional study, we assessed effects of calcineurin inhibitor (CNI) or rapamycin on T-regulatory (Treg) cells from children with stable liver (n = 53) or kidney (n = 9) allografts several years posttransplant. We analyzed Treg number, phenotype, suppressive function, and methylation at the Treg-specific demethylation region (TSDR) using Tregs and peripheral blood mononuclear cells. Forty-eight patients received CNI (39 as monotherapy) and 12 patients received rapamycin (9 as monotherapy). Treg numbers diminished over time on either regimen, but reached significance only with CNI (r =-0.424, p = 0.017). CNI levels inversely correlated with Treg number (r =-0.371, p = 0.026), and positively correlated with CD127+ expression by Tregs (r = 0.437, p = 0.023). Patients with CNI levels >3.6 ng/mL had weaker Treg function than those with levels <3.6 ng/mL, whereas rapamycin therapy positively correlated with Treg numbers (r = 0.628, p = 0.029) and their expression of CTLA4 (r = 0.726, p = 0.041). Overall, CTLA4 expression, TSDR demethylation and an absence of CD127 were important for Treg suppressive function. We conclude that rapamycin has beneficial effects on Treg biology, whereas long-term and high dose CNI use may impair Treg number, function and phenotype, potentially acting as a barrier to attaining host hyporesponsiveness to an allograft. © Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22994804      PMCID: PMC3513508          DOI: 10.1111/j.1600-6143.2012.04269.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  30 in total

1.  Acute rejection after liver transplantation: Is there a specific immunological pattern?

Authors:  O Perrella; C Sbreglia; G Arenga; A Perrella; A Ferrara; A D'Antonio; G Di Costanzo; L Atripaldi; C Alone; D Sciano; O Cuomo
Journal:  Transplant Proc       Date:  2006-12       Impact factor: 1.066

2.  A potential side effect of cyclosporin A: inhibition of CD4(+)CD25(+) regulatory T cells in mice.

Authors:  Hongjun Wang; Liang Zhao; Zuyue Sun; Liguang Sun; Baojun Zhang; Yong Zhao
Journal:  Transplantation       Date:  2006-12-15       Impact factor: 4.939

3.  Multiparameter immune profiling of operational tolerance in liver transplantation.

Authors:  M Martínez-Llordella; I Puig-Pey; G Orlando; M Ramoni; G Tisone; A Rimola; J Lerut; D Latinne; C Margarit; I Bilbao; S Brouard; M Hernández-Fuentes; J-P Soulillou; A Sánchez-Fueyo
Journal:  Am J Transplant       Date:  2007-02       Impact factor: 8.086

4.  Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients.

Authors:  David San Segundo; Juan Carlos Ruiz; María Izquierdo; Gema Fernández-Fresnedo; Carlos Gómez-Alamillo; Ramón Merino; María Jesús Benito; Eva Cacho; Emilio Rodrigo; Rosa Palomar; Marcos López-Hoyos; Manuel Arias
Journal:  Transplantation       Date:  2006-08-27       Impact factor: 4.939

5.  Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation.

Authors:  Takaaki Koshiba; Ying Li; Mami Takemura; Yanling Wu; Shimon Sakaguchi; Nagahiro Minato; Kathryn J Wood; Hironori Haga; Mikiko Ueda; Shinji Uemoto
Journal:  Transpl Immunol       Date:  2006-11-10       Impact factor: 1.708

6.  Low circulating regulatory T-cell levels after acute rejection in liver transplantation.

Authors:  Ahmet Demirkiran; Alice Kok; Jaap Kwekkeboom; Johannes G Kusters; Herold J Metselaar; Hugo W Tilanus; Luc J W van der Laan
Journal:  Liver Transpl       Date:  2006-02       Impact factor: 5.799

7.  Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells.

Authors:  Jun Wang; Andreea Ioan-Facsinay; Ellen I H van der Voort; Tom W J Huizinga; René E M Toes
Journal:  Eur J Immunol       Date:  2007-01       Impact factor: 5.532

8.  Molecular mechanisms underlying FOXP3 induction in human T cells.

Authors:  Pierre-Yves Mantel; Nadia Ouaked; Beate Rückert; Christian Karagiannidis; Roland Welz; Kurt Blaser; Carsten B Schmidt-Weber
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

9.  Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells.

Authors:  W Gao; Y Lu; B El Essawy; M Oukka; V K Kuchroo; T B Strom
Journal:  Am J Transplant       Date:  2007-05-19       Impact factor: 8.086

10.  Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production.

Authors:  Robert Zeiser; Vu H Nguyen; Andreas Beilhack; Martin Buess; Stephan Schulz; Jeanette Baker; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

View more
  55 in total

Review 1.  Immune profiling and cancer post transplantation.

Authors:  Christopher Martin Hope; Patrick Toby H Coates; Robert Peter Carroll
Journal:  World J Nephrol       Date:  2015-02-06

2.  Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region.

Authors:  Maura Rossetti; Roberto Spreafico; Suzan Saidin; Camillus Chua; Maryam Moshref; Jing Yao Leong; York Kiat Tan; Julian Thumboo; Jorg van Loosdregt; Salvatore Albani
Journal:  J Immunol       Date:  2014-12-01       Impact factor: 5.422

3.  Central Role of CD45RA- Foxp3hi Memory Regulatory T Cells in Clinical Kidney Transplantation Tolerance.

Authors:  Faouzi Braza; Emilie Dugast; Ivo Panov; Chloé Paul; Katrin Vogt; Annaick Pallier; Mélanie Chesneau; Daniel Baron; Pierrick Guerif; Hong Lei; David-Axel Laplaud; Hans-Dieter Volk; Nicolas Degauque; Magali Giral; Jean-Paul Soulillou; Birgit Sawitzki; Sophie Brouard
Journal:  J Am Soc Nephrol       Date:  2015-01-02       Impact factor: 10.121

4.  IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors.

Authors:  Gavin Whitehouse; Elizabeth Gray; Sotiris Mastoridis; Elliot Merritt; Elisavet Kodela; Jennie H M Yang; Richard Danger; Marta Mairal; Sofia Christakoudi; Juan J Lozano; Iain C Macdougall; Timothy I M Tree; Alberto Sanchez-Fueyo; Marc Martinez-Llordella
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-05       Impact factor: 11.205

5.  Adoptive Cell Therapy with Tregs to Improve Transplant Outcomes: The Promise and the Stumbling Blocks.

Authors:  Mohamed B Ezzelarab; Angus W Thomson
Journal:  Curr Transplant Rep       Date:  2016-10-25

Review 6.  Monitoring alloimmune response in kidney transplantation.

Authors:  Oriol Bestard; Paolo Cravedi
Journal:  J Nephrol       Date:  2016-05-31       Impact factor: 3.902

7.  The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients.

Authors:  Kyoung Woon Kim; Byung Ha Chung; Bo-Mi Kim; Mi-La Cho; Chul Woo Yang
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

8.  Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction.

Authors:  Joshua M Diamond; Tatiana Akimova; Altaf Kazi; Rupal J Shah; Edward Cantu; Rui Feng; Matthew H Levine; Steven M Kawut; Nuala J Meyer; James C Lee; Wayne W Hancock; Richard Aplenc; Lorraine B Ware; Scott M Palmer; Sangeeta Bhorade; Vibha N Lama; Ann Weinacker; Jonathan Orens; Keith Wille; Maria Crespo; David J Lederer; Selim Arcasoy; Ejigayehu Demissie; Jason D Christie
Journal:  Am J Respir Crit Care Med       Date:  2014-03-01       Impact factor: 21.405

Review 9.  Pharmacologic targeting of regulatory T cells for solid organ transplantation: current and future prospects.

Authors:  Kassem Safa; Sindhu Chandran; David Wojciechowski
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 10.  Impact of Immune-Modulatory Drugs on Regulatory T Cell.

Authors:  Akiko Furukawa; Steven A Wisel; Qizhi Tang
Journal:  Transplantation       Date:  2016-11       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.